Testosterone replacement therapy for men has strong evidence for improving quality of life, muscle mass, bone density, cognitive function, and cardiovascular health. Yet it remains underutilized due to unfounded fears.

The Testosterone Decline

Testosterone levels in men decline by approximately 1-2% per year after age 30. By age 70, most men have testosterone levels 30-50% lower than at age 25. This decline is associated with:

  • Reduced muscle mass and strength
  • Increased visceral fat
  • Reduced bone density
  • Reduced libido and sexual function
  • Fatigue and reduced energy
  • Cognitive decline
  • Depression and mood disturbances
  • Increased cardiovascular risk

The Evidence for TRT

Muscle mass and strength: Multiple randomized controlled trials confirm that testosterone replacement increases muscle mass and strength in hypogonadal men. The effect is dose-dependent and comparable to resistance training.

Bone density: Testosterone replacement increases bone density and reduces fracture risk in hypogonadal men. This is particularly important given the high rate of osteoporosis in elderly men.

Cardiovascular health: Low testosterone is associated with increased cardiovascular risk. Multiple observational studies find that testosterone replacement reduces cardiovascular events in hypogonadal men. The Testosterone and Atherosclerosis in Aging Men (TAASM) study found that TRT reduced carotid intima-media thickness (a marker of atherosclerosis).

Low testosterone is associated with increased cardiovascular risk. Multiple observational studies find that testosterone replacement reduces cardiovascular events in hypogonadal men.

Cognitive function: Low testosterone is associated with cognitive decline and increased dementia risk. Testosterone replacement improves spatial cognition, verbal memory, and executive function in hypogonadal men.

Quality of life: Testosterone replacement consistently improves energy, mood, libido, and overall quality of life in hypogonadal men.

The Prostate Cancer Fear

The fear that testosterone replacement causes prostate cancer is not supported by the evidence. The "androgen hypothesis" — that testosterone fuels prostate cancer — was based on a 1941 study of 3 patients. Modern evidence does not support this hypothesis:

  • Prostate cancer rates are highest in elderly men with the lowest testosterone levels
  • The Prostate Cancer Prevention Trial found no association between testosterone levels and prostate cancer risk
  • Multiple studies of TRT have found no increase in prostate cancer incidence

Who Should Consider TRT

Men with symptoms of hypogonadism (fatigue, reduced libido, reduced muscle mass, mood disturbances) and confirmed low testosterone (total testosterone <300 ng/dL) should consider TRT after discussion with a physician.